Nocentini A, Supuran CT and Winum JY. Benzoxaborole compounds for therapeutic uses: a patent review (2010- 2018). Expert Opin Ther Pat. 2018 May 11:1-12. https://doi.org/10.1080/13543776.2018.1473379
When the article was first published online, the second paragraph of section 2.5 contained an error. This has now been corrected in both the print and online versions as below.
2.5 Anti-inflammatory activity
Synthesis and SAR studies of 18 substituted phenoxybenzoxaborole derivatives were reported as anti-inflammatory agents. These compounds demonstrated inhibitory activities against the PDE4 enzyme and inflammation-related cytokine release. In vivo efficacy in mice models by topical application allowed the selection of the 5-(4-cyanophenoxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN 2728, crisaborole 3, Figure 3) for further development. This compound successively completed the different phases of clinical trials and was approved by FDA in December 2016 for the treatment of patients with mild to moderate atopic dermatitis” (ref: EUCRISA – crisaborole ointment, [package insert]. New York, NY: Pfizer Laboratories Div Pfizer Inc; 2017). It is currently the first and only non-steroidal monotherapy inhibiting PDE-4 enzyme in the skin. Crisaborole is marketed in the United States under the trade name EUCRISA [90].